These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 36803159)

  • 1. Scope of, Motivations for, and Outcomes Associated with Buprenorphine Diversion in the United States: A Scoping Review.
    Rubel SK; Eisenstat M; Wolff J; Calevski M; Mital S
    Subst Use Misuse; 2023; 58(5):685-697. PubMed ID: 36803159
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Examining buprenorphine diversion through a harm reduction lens: an agent-based modeling study.
    Adams JW; Duprey M; Khan S; Cance J; Rice DP; Bobashev G
    Harm Reduct J; 2023 Oct; 20(1):150. PubMed ID: 37848945
    [TBL] [Abstract][Full Text] [Related]  

  • 3. On my own terms: Motivations for self-treating opioid-use disorder with non-prescribed buprenorphine.
    Silverstein SM; Daniulaityte R; Miller SC; Martins SS; Carlson RG
    Drug Alcohol Depend; 2020 May; 210():107958. PubMed ID: 32203863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How Motivations for Using Buprenorphine Products Differ From Using Opioid Analgesics: Evidence from an Observational Study of Internet Discussions Among Recreational Users.
    Butler SF; Oyedele NK; Dailey Govoni T; Green JL
    JMIR Public Health Surveill; 2020 Mar; 6(1):e16038. PubMed ID: 32209533
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Buprenorphine in the United States: Motives for abuse, misuse, and diversion.
    Chilcoat HD; Amick HR; Sherwood MR; Dunn KE
    J Subst Abuse Treat; 2019 Sep; 104():148-157. PubMed ID: 31370979
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Has the treatment gap for opioid use disorder narrowed in the U.S.?: A yearly assessment from 2010 to 2019".
    Krawczyk N; Rivera BD; Jent V; Keyes KM; Jones CM; Cerdá M
    Int J Drug Policy; 2022 Dec; 110():103786. PubMed ID: 35934583
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Understanding the use of diverted buprenorphine.
    Cicero TJ; Ellis MS; Chilcoat HD
    Drug Alcohol Depend; 2018 Dec; 193():117-123. PubMed ID: 30359928
    [TBL] [Abstract][Full Text] [Related]  

  • 8. County-level sociodemographic differences in availability of two medications for opioid use disorder: United States, 2019.
    Corry B; Underwood N; Cremer LJ; Rooks-Peck CR; Jones C
    Drug Alcohol Depend; 2022 Jul; 236():109495. PubMed ID: 35605533
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Receipt of Telehealth Services, Receipt and Retention of Medications for Opioid Use Disorder, and Medically Treated Overdose Among Medicare Beneficiaries Before and During the COVID-19 Pandemic.
    Jones CM; Shoff C; Hodges K; Blanco C; Losby JL; Ling SM; Compton WM
    JAMA Psychiatry; 2022 Oct; 79(10):981-992. PubMed ID: 36044198
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Availability of Medications for the Treatment of Opioid Use Disorder Among Pregnant and Postpartum Individuals in US Jails.
    Sufrin C; Kramer CT; Terplan M; Fiscella K; Olson S; Voegtline K; Latkin C
    JAMA Netw Open; 2022 Jan; 5(1):e2144369. PubMed ID: 35050354
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Utilization of Medications for Opioid Use Disorder Across US States: Relationship to Treatment Availability and Overdose Mortality.
    Krawczyk N; Jent V; Hadland SE; Cerdá M
    J Addict Med; 2022 Jan-Feb 01; 16(1):114-117. PubMed ID: 35120067
    [TBL] [Abstract][Full Text] [Related]  

  • 12. College students' perceived knowledge of and perceived helpfulness of treatments for opioid use disorder at two American universities.
    Andraka-Christou B; Nguyen T; Harris S; Madeira J; Totaram R; Randall-Kosich O; Atkins D; Ford J
    Am J Drug Alcohol Abuse; 2020 Sep; 46(5):589-603. PubMed ID: 32543922
    [No Abstract]   [Full Text] [Related]  

  • 13. Medications for opioid use disorder in state prisons: Perspectives of formerly incarcerated persons.
    Treitler PC; Enich M; Reeves D; Crystal S
    Subst Abus; 2022; 43(1):964-971. PubMed ID: 35420973
    [No Abstract]   [Full Text] [Related]  

  • 14. Medication treatment for opioid use disorder in the age of COVID-19: Can new regulations modify the opioid cascade?
    Nunes EV; Levin FR; Reilly MP; El-Bassel N
    J Subst Abuse Treat; 2021 Mar; 122():108196. PubMed ID: 33221125
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug use patterns and factors related to the use and discontinuation of medications for opioid use disorder in the age of fentanyl: findings from a mixed-methods study of people who use drugs.
    Hughto JMW; Tapper A; Rapisarda SS; Stopka TJ; Palacios WR; Case P; Silcox J; Moyo P; Green TC
    Subst Abuse Treat Prev Policy; 2023 May; 18(1):30. PubMed ID: 37217975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. "I'm Not a Good Drug Dealer": Styles of Buprenorphine Diversion in a Multisite Qualitative Study.
    McLean K; Kavanaugh PR
    Subst Use Misuse; 2022; 57(3):452-460. PubMed ID: 35067160
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association between treatment setting and outcomes among oregon medicaid patients with opioid use disorder: a retrospective cohort study.
    Hartung DM; Markwardt S; Johnston K; Geddes J; Baker R; Leichtling G; Hildebran C; Chan B; Cook RR; McCarty D; Ghitza U; Korthuis PT
    Addict Sci Clin Pract; 2022 Aug; 17(1):45. PubMed ID: 35986384
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Opioid treatment programs, telemedicine and COVID-19: A scoping review.
    Chan B; Bougatsos C; Priest KC; McCarty D; Grusing S; Chou R
    Subst Abus; 2022; 43(1):539-546. PubMed ID: 34520702
    [No Abstract]   [Full Text] [Related]  

  • 19. Medicaid Prescription Cap Policies: Another Structural Barrier to Medication for Opioid Use Disorder.
    Hughto JMW; Moyo P; Green TC
    J Addict Med; 2022 Nov-Dec 01; 16(6):616-618. PubMed ID: 35245915
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Developing a cascade of care for opioid use disorder among individuals in jail.
    Ray B; Victor G; Cason R; Hamameh N; Kubiak S; Zettner C; Dunnigan M; Comartin E; Costello M
    J Subst Abuse Treat; 2022 Jul; 138():108751. PubMed ID: 35241352
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.